Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Juli 2021 08:00 ET | Quelle: Alkahest, Inc.

Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
08. März 2021 13:00 ET | Quelle: Alkahest, Inc.

Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
28. Januar 2021 08:00 ET | Quelle: Alkahest, Inc.

Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease

SAN CARLOS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
09. Juli 2020 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Provides Corporate Update

SAN CARLOS, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
01. Juni 2020 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients

SAN CARLOS, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
10. Februar 2020 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïve Wet Age-Related Macular Degeneration

SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...
04. Februar 2020 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

SAN CARLOS, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
17. Dezember 2019 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration

SAN CARLOS, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today...
09. Dezember 2019 07:30 ET | Quelle: Alkahest, Inc.

Alkahest Presents Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease

Clinical results presented Saturday, December 7th at CTAD 2019 Data support continued clinical development in randomized placebo controlled clinical trials SAN CARLOS, Calif., Dec. 09, 2019 ...
02. Dezember 2019 07:30 ET | Quelle: Alkahest, Inc.

Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference

SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related...

Nächste Seite